AC
ITOS

Aristides Capital’s iTeos Therapeutics ITOS Stock Holding History

Aristides Capital’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,360
Closed -$157K – 308
2023
Q4 		$157K Buy
+14,360
New +$142K 0.06% 229

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Aristides Capital's ITOS Position: Q1 2024 in Review

Aristides Capital sold out of iTeos Therapeutics (ITOS) in Q1 2024, closing a stake of 14,360 shares — an estimated $157K sold.

Aristides Capital first reported a position in ITOS in Q4 2023 and held it in 1 quarter. The position peaked at $157K in Q4 2023. 135 funds tracked by Wall St. Rank hold ITOS as of Q1 2024.

  • Aristides Capital reported no remaining iTeos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Aristides Capital sold 14,360 iTeos Therapeutics shares in Q1 2024, an estimated $157K.
  • Aristides Capital first reported a position in iTeos Therapeutics in Q4 2023 and held it in 1 quarter.
  • Aristides Capital's iTeos Therapeutics position peaked at $157K in Q4 2023.
  • 135 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.